-
公开(公告)号：US20210107980A1
公开(公告)日：2021-04-15
申请号：US17053346
申请日：2019-05-07
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US20210308208A1
公开(公告)日：2021-10-07
申请号：US17268387
申请日：2019-08-14
Applicant: Genmab A/S
Inventor： Reshma A. RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Bart DE GOEIJ , Oyewale O. ABIDOYE , Leonardo V. NICACIO , Stephen C. ALLEY
Abstract: The invention provides methods and compositions for treating cancer, such as ovarian cancer, peritoneal cancer, and fallopian tube cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., ovarian cancer, peritoneal cancer, and fallopian tube cancer).
-
公开(公告)号：US20220387485A1
公开(公告)日：2022-12-08
申请号：US17771784
申请日：2020-11-06
Applicant: Genmab A/S
Inventor： Reshma A RANGWALA , Esther C,W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo V. NICACIO
IPC: A61K33/243 , A61K31/555 , A61K47/68 , A61P35/00
Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
-
Patent Agency Ranking
公开(公告)号：US20210030888A1
公开(公告)日：2021-02-04
申请号：US16978539
申请日：2019-03-06
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Esther Cornelia Wilhelmina BREIJ , David SATIJN , Sandra VERPLOEGEN , Jantine BAKEMA , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Andreas LINGNAU
Abstract: The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).
-
公开(公告)号：US20230027495A1
公开(公告)日：2023-01-26
申请号：US17775279
申请日：2020-11-06
Applicant: Genmab A/S , MSD International GmbH
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US20220088191A1
公开(公告)日：2022-03-24
申请号：US17053753
申请日：2019-05-07
Applicant: Genmab A/S , MSD International GmbH
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
IPC: A61K39/395 , A61K47/68 , A61P35/00
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US20210402003A1
公开(公告)日：2021-12-30
申请号：US17289616
申请日：2019-10-28
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Sandra VERPLOEGEN , Esther C.W. BREIJ , Oyewale O. ABIDOYE , Leonardo Viana NICACIO
Abstract: The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.
-
公开(公告)号：US20210015939A1
公开(公告)日：2021-01-21
申请号：US16982008
申请日：2019-03-20
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO
IPC: A61K47/68 , A61P35/00 , A61K31/555 , A61K9/00
Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.017 seconds)
